Loading...
Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice
Glioblastoma (GBM) causes poor survival in patients even with aggressive treatment. Temozolomide (TMZ) is the standard chemotherapeutic choice for GBM treatment but resistance always ensues. Protein kinase CK2 (CK2) contributes to tumour development and proliferation in cancer, and it is overexpress...
Na minha lista:
| Udgivet i: | Pharmaceuticals (Basel) |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5374428/ https://ncbi.nlm.nih.gov/pubmed/28208677 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph10010024 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|